147.90 0.00 (0.00%)
After hours: 5:06PM EST
|Bid||146.00 x 900|
|Ask||150.68 x 1000|
|Day's Range||147.35 - 150.19|
|52 Week Range||53.30 - 155.85|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||305.58|
|Earnings Date||Feb 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||150.75|
Biotech stocks got some reprieve in this week amid the release of earnings, clinical trial results presentations and positive FDA actions. Among the noteworthy developments of the week: The FDA panel ruling ...
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vivian Wohl, co-manager of the Federated Kaufman Small Cap fund, digs deep when researching medical devices and health-care software. Why she likes the stocks of Inspire Medical Systems, Veeva Systems, and others
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
Dexcom Inc NASDAQ/NGS:DXCMView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for DXCM with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding DXCM totaled $2.00 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.
CNBC's Jim Cramer says a Dexcom-Apple merger could be an “unbelievable” move for the iPhone maker. The "Mad Money" host also speaks with Clorox CEO Benno Dorer after earnings. In the lightning round, Cramer pinpoints the one regional bank that's not worrying him.
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Cerner's (CERN) fourth-quarter 2018 results are likely to be hurt by year-over-year decline in bookings; Q4 guidance promising.
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
AmerisourceBergen's (ABC) first-quarter fiscal 2019 results are likely to gain from its core Pharmaceutical Distribution business unit.